1-2 of 2
J. D. Karkera, PhD
Close
Sort by
Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD
Journal: Blood
Blood (2012) 120 (21): 1508.
https://doi.org/10.1182/blood.V120.21.1508.1508
Published: 2012
Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD, Weimin Li, Erin D Henitz, BS, J. D. Karkera, PhD, Reyna Favis, PhD, Dana Gaffney, MS, Alice Shapiro, MS, Panteli Theocharous, BSc (hons), MSc, PhD, Yusri A Elsayed, MD, PhD, Helgi van de Velde, MD, PhD, Evgenii A Osmanov, MD, PhD, Xiaonan Hong, MD, Adriana Scheliga, MD, Fritz C. Offner, MD, PhD, Simon Rule, Adriana C Teixeira, MD, Jan Walewski, MD, PhD, Sven de Vos, MD, PhD, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Pier Luigi Zinzani, MD, PhD, Andrew Z Cakana, MD, FRCPath, Dixie-Lee Esseltine, MD, FRCPC, George Mulligan, PhD, Deborah S Ricci, PhD
Journal: Blood
Blood (2011) 118 (21): 265.
https://doi.org/10.1182/blood.V118.21.265.265
Published: 2011